Abstract
Retinoblastoma is the most common pediatric ocular cancer. This cancer occurs due to malignancy in retinoblast cells, which are precursors of photoreceptors, horizontal cells, amacrine cells, muller cells, and retinal progenitor cells in the retina of the eye. Genetic correlation has been observed in most cases of retinoblastoma. It is caused due to the suppression or mutation of the retinoblastoma 1 gene (RB1 gene), which is located at the 14th band of both alleles of the 13th human chromosome. RB1 gene is a tumour suppressor gene responsible for regulating cell growth and controlling abnormal cell division. In the last two decades, as accurate identification of characteristic features of cancer cells at various stages of retinoblastoma has been made, we can now plan more advanced and personalized management of the disease due to improved and focused therapeutic effects of cryotherapy, thermotherapy, radiotherapy, chemotherapy, and surgical interventions. These efforts can lead to a better survival rate with reduced damage to the non-cancerous cells in the eyeball, promoting better visual performance (better visual acuity and visual axis alignment). Based on studies published in PubMed and Google Scholar till 2023, current treatment options at various stages of retinoblastoma are reviewed to suggest the most promising treatment options. Based on this information, a clear treatment flowchart has been prepared. This review article can assist researchers, eye specialists, geneticists, and cancer specialists in determining the most promising method for treating retinoblastoma at various stages.
Keywords: Retinoblastoma, ocular carcinoma, retinoblast cells, progenitor cells, RB genes, cryotherapy, thermotherapy, radiotherapy, chemotherapy.
Current Cancer Therapy Reviews
Title:Present Scenario and Future Prospects in the Management of Retinoblastoma: A Review
Volume: 21 Issue: 1
Author(s): Vikas Shrivastava*, Pramod Kumar Sharma, Kamal Pant and Rahul Banik
Affiliation:
- Department of Optometry, School of Medical and Allied Sciences, Galgotia University, Gautam Buddha Nagar U.P. India
Keywords: Retinoblastoma, ocular carcinoma, retinoblast cells, progenitor cells, RB genes, cryotherapy, thermotherapy, radiotherapy, chemotherapy.
Abstract: Retinoblastoma is the most common pediatric ocular cancer. This cancer occurs due to malignancy in retinoblast cells, which are precursors of photoreceptors, horizontal cells, amacrine cells, muller cells, and retinal progenitor cells in the retina of the eye. Genetic correlation has been observed in most cases of retinoblastoma. It is caused due to the suppression or mutation of the retinoblastoma 1 gene (RB1 gene), which is located at the 14th band of both alleles of the 13th human chromosome. RB1 gene is a tumour suppressor gene responsible for regulating cell growth and controlling abnormal cell division. In the last two decades, as accurate identification of characteristic features of cancer cells at various stages of retinoblastoma has been made, we can now plan more advanced and personalized management of the disease due to improved and focused therapeutic effects of cryotherapy, thermotherapy, radiotherapy, chemotherapy, and surgical interventions. These efforts can lead to a better survival rate with reduced damage to the non-cancerous cells in the eyeball, promoting better visual performance (better visual acuity and visual axis alignment). Based on studies published in PubMed and Google Scholar till 2023, current treatment options at various stages of retinoblastoma are reviewed to suggest the most promising treatment options. Based on this information, a clear treatment flowchart has been prepared. This review article can assist researchers, eye specialists, geneticists, and cancer specialists in determining the most promising method for treating retinoblastoma at various stages.
Export Options
About this article
Cite this article as:
Shrivastava Vikas*, Kumar Sharma Pramod, Pant Kamal and Banik Rahul, Present Scenario and Future Prospects in the Management of Retinoblastoma: A Review, Current Cancer Therapy Reviews 2025; 21 (1) . https://dx.doi.org/10.2174/0115733947245338240108011058
DOI https://dx.doi.org/10.2174/0115733947245338240108011058 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Tumor Immune Microenvironment by Sphingolipids and
Lysophosphatidic Acid
Current Drug Targets Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Neuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration
Current Molecular Medicine Physiology and Pharmacology of Two-Pore Domain Potassium Channels
Current Pharmaceutical Design Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Ultrasound Elastography in Ocular and Periocular Tissues: A Review
Current Medical Imaging BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Liver Stem Cells: From Preface to Advancements
Current Stem Cell Research & Therapy Neurochemistry Changes Associated with Mutations in Familial Parkinsons Disease
Current Medicinal Chemistry Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease
Current Medicinal Chemistry Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Silver Nanoparticles in Cancer: Therapeutic Efficacy and Toxicity
Current Medicinal Chemistry Electron Microscopy in Antiparasitic Chemotherapy: A (Close) View to a Kill
Current Drug Targets Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety